Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 250 entries
View as:

Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05356169 Org: User:
Start: 05/19/22 End: 10/15/27 Due: 10/15/28

Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT05531266 Org: User:
Start: 09/01/22 End: 03/01/25 Due: 03/01/26

National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT07019038 Org: User:
Start: 01/01/01 End: 12/31/70 Due: 12/31/71

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT06561880 Org: User:
Start: 10/08/24 End: 08/31/26 Due: 08/31/27

Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

Phase: N/A Priority: Normal
NCT ID: NCT02937662 Org: User:
Start: 10/31/16 End: 04/30/20 Due: 04/30/21

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06066242 Org: User:
Start: 10/01/23 End: 10/10/25 Due: 10/10/26

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

Phase: N/A Priority: Normal
NCT ID: NCT03021330 Org: User:
Start: 02/08/17 End: 10/15/27 Due: 10/15/28

Efficacy of Decitabine in Clearance of MRD

Phase: N/A Priority: Normal
NCT ID: NCT03021395 Org: User:
Start: 02/08/17 End: 12/31/22 Due: 12/31/23

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05456698 Org: User:
Start: 10/18/22 End: 12/30/25 Due: 12/30/26

Venetoclax and Ivosidenib Combined With Chemotherapy in IDH1 Mutated AML

Phase: N/A Priority: Normal
NCT ID: NCT06611839 Org: User:
Start: 10/30/25 End: 10/01/28 Due: 10/01/29

Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06613880 Org: User:
Start: 10/24/24 End: 09/30/26 Due: 09/30/27

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05137886 Org: User:
Start: 01/31/22 End: 01/31/25 Due: 01/31/26

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03173612 Org: User:
Start: 08/31/16 End: 12/31/24 Due: 12/31/25

CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.

Phase: N/A Priority: Normal
NCT ID: NCT06733610 Org: User:
Start: 12/05/24 End: 12/05/26 Due: 12/05/27

Prospective Observational Clinical Study on Changes in Cognitive Levels in Elderly Patients Before and After Hematopoietic Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT06484049 Org: User:
Start: 07/30/24 End: 05/31/26 Due: 05/31/27

Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients

Phase: N/A Priority: Normal
NCT ID: NCT04696705 Org: User:
Start: 12/31/20 End: 12/25/23 Due: 12/25/24

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)

Phase: N/A Priority: Normal
NCT ID: NCT01760096 Org: User:
Start: 01/31/13 End: 07/31/17 Due: 07/31/18

R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL

Phase: N/A Priority: Normal
NCT ID: NCT04992377 Org: User:
Start: 08/30/21 End: 08/30/25 Due: 08/30/26

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05676697 Org: User:
Start: 01/13/23 End: 02/06/24 Due: 02/06/25

Reproductive and Mental Health of Patients With Aplastic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT06936930 Org: User:
Start: 03/03/25 End: 12/31/27 Due: 12/31/28

Ruxolitinib as GVHD Prophylaxis in AA Patients

Phase: N/A Priority: Normal
NCT ID: NCT05914714 Org: User:
Start: 07/01/23 End: 05/01/25 Due: 05/01/26

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05913804 Org: User:
Start: 06/15/23 End: 12/30/25 Due: 12/30/26

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

Phase: N/A Priority: Normal
NCT ID: NCT05287984 Org: User:
Start: 03/22/22 End: 11/29/24 Due: 11/29/25

A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04316624 Org: User:
Start: 09/29/19 End: 02/08/23 Due: 02/08/24

Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05519384 Org: User:
Start: 09/14/22 End: 12/31/25 Due: 12/31/26